D.E. Shaw & Co
ZVRA icon

D.E. Shaw & Co’s Zevra Therapeutics ZVRA Stock Holding History

D.E. Shaw & Co’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
1,306,949
+460,492
+54% +$5.12M 0.01% 1325
2026
Q1 		$7.89M Sell
846,457
-17,289
-2% -$156K ﹤0.01% 1821
2025
Q4 		$7.74M Buy
863,746
+137,916
+19% +$1.3M ﹤0.01% 1968
2025
Q3 		$6.9M Buy
725,830
+536,517
+283% +$5.38M ﹤0.01% 1954
2025
Q2 		$1.67M Buy
189,313
+161,943
+592% +$1.31M ﹤0.01% 2873
2025
Q1 		$205K Buy
27,370
+2,295
+9% +$18.2K ﹤0.01% 3924
2024
Q4 		$209K Buy
+25,075
New +$214K ﹤0.01% 4065
2022
Q2 		– Sell
-10,453
Closed -$53K – 5840
2022
Q1 		$53K Sell
10,453
-13,356
-56% -$85K ﹤0.01% 5132
2021
Q4 		$207K Buy
+23,809
New +$212K ﹤0.01% 4867

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

D.E. Shaw & Co's ZVRA Position: Q2 2026 in Review

D.E. Shaw & Co increased its Zevra Therapeutics (ZVRA) stake by 54% in Q2 2026, buying an estimated $5.12M and bringing the position to 1,306,949 shares worth $18.7M. The position accounts for 0.01% of the portfolio, ranked #1325.

D.E. Shaw & Co first reported a position in ZVRA in Q4 2021 and has held it in 9 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • D.E. Shaw & Co held 1,306,949 shares of Zevra Therapeutics worth $18.7M as of Q2 2026.
  • D.E. Shaw & Co bought 460,492 Zevra Therapeutics shares in Q2 2026, an estimated $5.12M.
  • Zevra Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1325 holding.
  • D.E. Shaw & Co first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 9 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.